Munich Reinsurance Co Stock Corp in Munich Sells 237,281 Shares of Merck & Co., Inc. $MRK

Munich Reinsurance Co Stock Corp in Munich decreased its position in Merck & Co., Inc. (NYSE:MRK) by 24.0% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 752,637 shares of the company’s stock after selling 237,281 shares during the period. Merck & Co., Inc. comprises 2.2% of Munich Reinsurance Co Stock Corp in Munich’s portfolio, making the stock its 7th biggest position. Munich Reinsurance Co Stock Corp in Munich’s holdings in Merck & Co., Inc. were worth $90,535,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Kingdom Financial Group LLC. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Abound Financial LLC acquired a new position in Merck & Co., Inc. during the fourth quarter worth $26,000. Prosperity Bancshares Inc acquired a new position in Merck & Co., Inc. during the fourth quarter worth $26,000. United Financial Planning Group LLC bought a new position in Merck & Co., Inc. in the third quarter valued at $31,000. Finally, High Note Wealth LLC grew its position in Merck & Co., Inc. by 58.9% in the fourth quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $126.10 on Thursday. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02. The company’s fifty day simple moving average is $118.27 and its 200 day simple moving average is $116.06. Merck & Co., Inc. has a 1-year low of $76.66 and a 1-year high of $130.29. The company has a market cap of $311.45 billion, a price-to-earnings ratio of 35.52, a PEG ratio of 2.75 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) EPS for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same quarter last year, the company posted $2.22 earnings per share. The company’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. On average, research analysts forecast that Merck & Co., Inc. will post 5.19 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were paid a $0.85 dividend. This represents a $3.40 annualized dividend and a yield of 2.7%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is 95.77%.

Merck & Co., Inc. News Summary

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed its outperform rating on Merck and set a $142 price target, signaling meaningful upside from current levels. Benzinga report on RBC rating
• Positive Sentiment: Wells Fargo raised its price target on Merck to $150 and kept an overweight rating, adding to the bullish analyst tone around the stock. Benzinga report on Wells Fargo price target
• Positive Sentiment: Merck’s recent KEYTRUDA approvals in breast and bladder cancer broaden the drug’s use in difficult-to-treat cancers and strengthen the company’s oncology franchise ahead of future exclusivity losses. Article on KEYTRUDA approvals
• Positive Sentiment: Merck also reached a new access agreement for its HIV treatment IDVYNSO, improving commercial access and adding another supportive development for the valuation story. Article on HIV access deal
• Neutral Sentiment: Merck is trading above both its 50-day and 200-day moving averages, which technically supports the stock, but the broader picture still includes patent expiry and vaccine-related concerns. Zacks technical analysis
• Neutral Sentiment: A separate research roundup highlighted Merck alongside other large-cap names, but did not introduce a new company-specific catalyst. Top Research Reports article
• Negative Sentiment: Some commentary noted Merck’s recent pullback and continuing investor focus on its post-Keytruda exclusivity outlook, which remains the main long-term risk to the stock. Article on valuation narrative

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Zacks Research raised shares of Merck & Co., Inc. from a “strong sell” rating to a “hold” rating in a research report on Tuesday, March 17th. CICC Research began coverage on Merck & Co., Inc. in a report on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 price objective for the company. Citigroup initiated coverage on Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 target price on the stock. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Finally, Weiss Ratings cut Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $132.11.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.